Last reviewed · How we verify
CODOX-M
At a glance
| Generic name | CODOX-M |
|---|---|
| Sponsor | Cooperative Study Group A for Hematology |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma (PHASE2)
- A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma (PHASE4)
- Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma (PHASE2)
- Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (PHASE2)
- A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CODOX-M CI brief — competitive landscape report
- CODOX-M updates RSS · CI watch RSS
- Cooperative Study Group A for Hematology portfolio CI